New triple therapy takes on hard-to-treat ovarian cancer
NCT ID NCT07239622
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of three drugs—liposomal irinotecan, sintilimab, and anlotinib—in 36 people with recurrent or persistent ovarian clear cell carcinoma. The goal is to see if the treatment can shrink tumors and control the disease. Participants must have already tried platinum-based chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- liposomal irinotecan, sintilimab, and anlotinib
- What this could lead to
- If successful, this combination could offer a new treatment option for people with recurrent ovarian clear cell carcinoma, potentially shrinking tumors and delaying disease progression.
- What could go wrong
- This is a small, early-phase trial with only 36 participants and no comparison group. The combination may cause significant side effects, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new PET tracer light up hidden cancers?
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?
- Can AI spot ovarian cancer on CT scans before It's too late?
- Can Lab-Grown tumors unlock the secrets of ovarian cancer resistance?
- Can a smart drug home in on Hard-to-Treat cancers?